Document is current
Any future updates will be listed below
-
Authors
Devos, Timothy https://orcid.org/0000-0002-6881-417X
Havelange, Violaine
Theunissen, Koen
Meers, Stef
Benghiat, Fleur Samantha
Gadisseur, Alain
Vanstraelen, Gaëtan
Vellemans, Hélène
Bailly, Benjamin
Granacher, Nikki
Lewalle, Philippe
De Becker, Ann
Van Eygen, Koen
Janssen, Mia
Triffet, Agnes
Vrelust, Inge
Deeren, Dries
Mazure, Dominiek
Bekaert, Julie
Beck, Michael
Selleslag, Dominik
-
Funding
Funding for this research was provided by:
Incyte Biosciences Benelux BV (Not applicable)
- License Information
-
More Information
Article History
Received: 28 July 2020
Accepted: 3 April 2021
First Online: 4 May 2021
Declarations
:
: Informed consent was obtained from all individual participants included in the registry, but a waiver was granted by the ethics committee for patients in the Named Patient Program who were still on ponatinib treatment on March 1, 2016 but deceased before the registry start.
: This registry was conducted in accordance with the ethical standards of the institutional and/or national ethics committees and with the Declaration of Helsinki and the International Council for Harmonization guidelines for good clinical practice.
: KT reports membership of advisory boards from multiple pharmaceutical companies. BB reports research funding from Incyte Biosciences Benelux BV. ADB reports ad hoc membership of advisory boards from multiple pharmaceutical companies. DD reports consultancy, honoraria, membership of Board of Directors or advisory committees, and research funding from multiple pharmaceutical companies. DS reports consultancy and travel expenses from Incyte Biosciences Benelux BV. JB and MB are employees of Incyte Biosciences. There are no relationships to disclose for TD, VH, SM, FSB, AG, GV, HV, NG, PL, KVE, MJ, AT, IV, and DM.
